Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC February Update

The Scottish Medicines Consortium has issued its monthly advice on new medicines.

Mesalazine has been accepted for mild and moderate exacerbations of ulcerative colitis and for maintenance of remission in ulcerative colitis and Crohn's disease.

Valsartan and losartan 100mg/hydrochlorothiazide 12.5mg have been accepted for the treatment of hypertension, the latter when monotherapy with either agent fails.

Glyceryl trinitrate 0.4% ointment (Rectogesic®) was rejected because the economic case was insufficiently robust to gain acceptance. This was the fourth submission to be rejected.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected medicines should be avoided.

Share 'SMC February Update' on Email Share 'SMC February Update' on Delicious Share 'SMC February Update' on Digg Share 'SMC February Update' on Facebook Share 'SMC February Update' on Google+ Share 'SMC February Update' on reddit Share 'SMC February Update' on StumbleUpon Share 'SMC February Update' on Twitter

atomic-wealth

One Comments to “SMC February Update”

  1. How's the medicine suiting you, sir?

    Trackback by Trusted.MD Network — February 19, 2008 #
    Reply

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,527 spam comments.

atomic-wealth
fond-illness
summer